DSIP vs Semax.

DSIP (Delta Sleep-Inducing Peptide) is a small endogenous nonapeptide with the amino acid sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (WAGGDASGE), molecular weight roughly 850 Da. It was first isolated in 1974 by Schoenenberger, Monnier and colleagues in Switzerland from the cerebral venous blood of rabbits placed in an electrically induced state of slow-wave (delta) sleep, and named for that apparent sleep-promoting property. DSIP-like immunoreactive material has since been detected in various mammalian tissues and human fluids (including breast milk), but it remains a biochemical "riddle": no gene, precursor protein, or specific receptor for it has been definitively identified.

Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) consisting of the ACTH(4-7) fragment of adrenocorticotropic hormone joined to a C-terminal Pro-Gly-Pro tripeptide. It was developed in the late 1980s/early 1990s at the Institute of Molecular Genetics of the Russian Academy of Sciences and is first described in the scientific literature around 1991. The Pro-Gly-Pro extension stabilizes the otherwise rapidly degraded ACTH fragment without retaining ACTH's hormonal (corticosteroid-releasing) activity, making Semax a "neuropeptide" rather than a hormone.

DSIP has no single confirmed receptor or signaling pathway; its mechanism remains genuinely unresolved despite decades of study. Reported preclinical interactions are diffuse and concentration-dependent, including modulation of NMDA-receptor activity, effects on glucocorticoid/stress-axis regulation, and engagement of MAPK signaling cascades, along with proposed influences on GABAergic, opioid/enkephalin, and somatostatin systems. It does not behave like a classical hypnotic acting at a defined target; instead it has been framed as a neuromodulator or "homeostatic" regulator with dose- and timing-dependent, sometimes bidirectional, effects on arousal. Its very short circulating half-life (on the order of minutes) further complicates any straightforward receptor-occupancy mechanism.

Semax is structurally derived from ACTH(4-10) but lacks the melanocortin-receptor-driven hormonal effects of full-length ACTH, so it does not stimulate cortisol release. Mechanistic (largely rodent and in vitro) work indicates it upregulates brain-derived neurotrophic factor (BDNF) and its receptor TrkB in the hippocampus, and modulates expression of NGF and other neurotrophic and immune-response genes, which is proposed to support neuronal survival and synaptic plasticity. A separate biochemical mechanism is inhibition of enkephalin-degrading enzymes in human serum (reported IC50 ~10 µM), which may prolong the activity of endogenous regulatory peptides. The relative contribution of each pathway to any observed clinical effect remains unsettled; Wikipedia and reviews note the precise mechanism of action is not definitively established.

Human data exist but are old, small, and mixed. Small studies from the early 1980s (e.g., Schneider-Helmert and colleagues, Experientia 1981; Int J Clin Pharmacol Ther Toxicol 1981) reported acute and delayed improvements in sleep efficiency, latency and continuity in insomniac and normal subjects after intravenous DSIP, with good tolerability. However, a later double-blind matched-pairs study in 16 chronic insomniacs (Neuropsychobiology, 1992) found higher sleep efficiency and shorter latency yet concluded short-term DSIP is "not likely to be of major therapeutic benefit." A 1984 clinical trial (European Neurology) and a pilot study in chronic pain also reported effects, and a 2009 anaesthesia study (European Journal of Anaesthesiology) found DSIP altered bispectral index/EEG as an isoflurane adjunct. A 2006 Journal of Neurochemistry review explicitly calls DSIP "a still unresolved riddle," underscoring that no modern, adequately powered, registration-quality trial has confirmed a clinical sleep benefit.

Human evidence comes almost entirely from Russian clinical research and is modest in scale. A representative controlled study by Gusev, Martynov and colleagues (Zh Nevrol Psikhiatr Im S S Korsakova, 2018; PMID 29798983) in 110 ischemic-stroke patients reported that semax plus early rehabilitation raised plasma BDNF and improved motor recovery and functional independence (Barthel index). The strongest mechanistic data, BDNF/TrkB upregulation (Brain Research, 2006; PMID 16996037) and neuroprotection and immune-gene regulation in rat ischemia (Mol Genet Genomics, 2017; PMID 28255762), are preclinical (rat/in vitro). Proposed uses such as ADHD or cognitive enhancement rest largely on hypothesis papers (e.g., Med Hypotheses, 2007; PMID 16996699) rather than rigorous trials. Crucially, no large, independent, randomized, double-blind Western trials have replicated the Russian findings, so the human cognitive- and stroke-benefit claims should be regarded as preliminary.

In the small historical human studies DSIP was generally described as well tolerated with few reported acute side effects, including reports of no daytime sedation hangover. However, these trials were tiny, short-term, and decades old, so the safety database is thin and there is essentially no modern controlled long-term safety, immunogenicity, or chronic-exposure data. Material sold for "research" is unregulated, of unverified purity and identity, and not produced to pharmaceutical standards, which introduces contamination and mislabeling risks independent of the peptide itself. Long-term effects, drug interactions, and effects in any specific population remain unknown.

Russian clinical reports and the intranasal route describe generally good tolerability, with mild nasal/local irritation the most commonly noted complaint; however, these data come from small studies without the long-term, independent safety surveillance expected for Western drug approval. There is no robust characterization of long-term safety, drug interactions, effects in pregnancy, or risks from non-pharmaceutical "research-use" material sold online, which may vary in purity and sterility. Because much of the mechanistic profile (BDNF/neurotrophin modulation, peptidase inhibition) is extrapolated from animal models, downstream effects of chronic human use are essentially unstudied. Product sold by online vendors is not manufactured to pharmaceutical standards and its identity and contaminants are not guaranteed.

DSIP is not approved by the FDA (or, to public knowledge, any major regulator) as a drug for sleep or any other indication; it has only ever been an investigational/experimental compound and is currently sold as a research-use-only chemical. It is not a WADA-prohibited substance by name, but it is not a legitimate, quality-controlled medicine.

Semax is approved as a prescription drug in Russia (and appears on Russia's List of Vital and Essential Drugs) for indications including ischemic stroke, transient ischemic attack, and cognitive disorders. It is not FDA-approved and is unscheduled in the United States, where it is sold by online vendors as a research/non-pharmaceutical product; it is not approved or marketed in most countries outside Russia.